site stats

Ceptaris therapeutics

WebCeptaris Therapeutics, Inc. Developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of … WebJun 5, 2012 · Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine …

Stephen Tullman, Chairman & CEO, Ceptaris Therapeutics - Topio …

WebCeptaris Therapeutics artrix 2024-09-09T20:49:05-07:00. Project Description. Project Details. Categories: North America Biopharm Exited Region Industry ... Visirna Therapeutics Inc. Gallery Visirna … WebFeb 21, 2012 · Ceptaris Therapeutics Inc is a privately held specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine … pshe association dental health https://boldinsulation.com

Ceptaris Therapeutics Company Profile: Acquisition

WebHer biotech career started with Ception Therapeutics as a Senior Accountant. Following Ception, she owned and operated her own accounting business, DanJenn, Inc. where she continued to work for various start-up biotech companies (Ceptaris Therapeutics, Inc., Velicept Therapeutics, Inc. and Onspira Therapeutics, Inc.) on a consulting basis. WebREVOLVING DOOR. 59 out of 72 Johnson & Johnson lobbyists in 2024 have previously held government jobs. Previously held government jobs: 81.94%. Did not previously hold government jobs: 18.06%. Previously held government jobs. pshe association body image

VALCHLOR (mechlorethamine) gel, for topical use medication …

Category:Actelion Acquires Ceptaris - Yahoo Finance

Tags:Ceptaris therapeutics

Ceptaris therapeutics

Jeffrey Wilkins Email & Phone Number - Avalo Th.. ZoomInfo

WebWellmond Therapeutics is a start-up pharmaceutical company located in Rockville, MD and was developing drug candidates in oncology supportive care and treatments for diseases and conditions involving mitochondrial and cellular energy disorders or failures. In addition, Mr. Guiheen has over 25 years of experience in the blood and plasma industry. WebRepresented Ceptaris Therapeutics in its acquisition by Actelion (Switzerland) for $250 million cash plus undisclosed milestone payments and sales earnouts. Represented a French CAC 40 company in connection with the sale …

Ceptaris therapeutics

Did you know?

WebJan 1, 2015 · Henkel was also Executive Vice President of Research and Development at Ception Therapeutics (acquired by Cephalon), Executive Vice President and Chief … WebJul 31, 2013 · Actelion Pharmaceuticals Ltd / Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible... April 5, 2024

WebCeptaris Therapeutics, Inc. produces and distributes pharmaceutical products. The Company offers prescription medications for the treatment of mycosis fungoides type of … WebDoing Business As: Ceptaris Therapeutics Inc Phone: 610-975-9290. Benten Bioservices, Inc. EIN Number: 02-0806340 Address: 347 Phoenixville Pike, Malvern, Pennsylvania, 19355 Doing Business As: Benten Bioservices Inc Phone: 610-854-4700. Phasebio Pharmaceuticals Inc. EIN Number: 03-0375697

WebJul 31, 2013 · Ceptaris Therapeutics Inc. is a privately held, specialty pharmaceutical company that was established to develop a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of ... WebNov 20, 2006 · Ceptaris Therapeutics Inc. is a specialty pharmaceutical company that was established to develop a proprietary gel formulation of mechlorethamine for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of CTCL. If approved, Ceptaris' investigational drug would be the first FDA-approved topical mechlorethamine product …

WebAug 26, 2013 · Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that has developed a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of stage IA ...

WebFeb 21, 2024 · Chief Medical Officer at Avalo Therapeutics "Dr. H. Jeffrey Wilkins is chief medical officer of Lycera. Dr. Wilkins brings over 15 years of clinical research experience, most recently serving as Clinical Lead and Partner of NeXeption, LLC, a biopharmaceutical management company. Previously, he was Chief Medical Officer and Head of Medical … pshe association contact numberWebLocations. Primary. 101 Lindenwood Drive Suite 400. Malvern, Pennsylvania 19355, US. Get directions. horseback riding camps in north carolinaWebActelion Ltd. in its acquisition of Ceptaris Therapeutics for $250 million upfront and additional royalty and potential milestone payments. Eisai Inc. in its divestiture of US rights to Gliadel® Wafer to Arbor Pharmaceuticals. Numerous emerging and leading biopharmaceutical, diagnostic and medical device companies in the U.S. rollout of Phase ... pshe association eyfsWebCeptaris developed VALCHLOR™, a proprietary gel formulation of mechlorethamine for the treatment of early stage (IA and IB) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). VALCHLOR was the first FDA-approved topical mechlorethamine product available to treat the signs and symptoms of this rare cancer. ... TerSera Therapeutics ... pshe association differentiationWebSep 20, 2013 · Actelion Ltd. ( ALIOF) completed the acquisition of privately-held Ceptaris Therapeutics. The acquisition closed on the heels of Ceptaris’ drug Valchlor gaining … pshe association conferenceWebStephen Tullman is Board member at Velicept Therapeutics. Tullman hass more than 23 years of biopharmaceutical global commercialization and drug development experience. … pshe association curriculum mapWebAug 1, 2013 · Date with density. The deal will see Actelion pay an additional $225m to acquire Pennsylvania-based Ceptaris on FDA approval of Valchlor, once known as Clearazide, and pending certain other undisclosed conditions. Formerly known as Yaupon Therapeutics, Ceptaris is on its second attempt to get the proprietary gel formulation of … horseback riding camps near me for summer